chemieunternehmen.com

Evotec SE participates in iCARE4CVD, an international public-private research consortium iCARE4CVD to better understand cardiovascular disease and optimise future prevention and treatment. The consortium brings together 33 leading international partners from civil society, academia and industry, and is led and coordinated by Maastricht University and global healthcare company Novo Nordisk. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-joins-icare4cvd-a-consortium-to-personalise-prevention-and-treatment-of-cardiovascular-diseases-6336

Evotec SE today announced a translational BRIDGE partnership with Pre-Amp, a new venture studio created by Amplitude Ventures, a full-stack venture capital firm focused on investing in precision medicine at the intersection of biology and machine learning.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-amplitude-ventures-launch-partnership-for-pre-amp-6334

Evotec SE today announced the official launch of the Cyprotex “e-Store”, offering simplified online access to the company’s comprehensive range of ADME-Tox services.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/cyprotex-launches-e-store-for-online-ordering-of-adme-tox-services-6332

Evotec SE today announced that the Company has entered into a new BRIDGE partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund. “65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new therapeutics companies in Singapore.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-clavystbio-leaps-by-bayer-lightstone-ventures-and-polaris-partners-launch-65lab-6330

Evotec SE today celebrated the Grand Opening of a new facility, Building 95 (“B95”), on the Company’s Dorothy Crowfoot Hodgkin Campus at Milton Park. Evotec has had a presence in Abingdon since the Company’s acquisition of Oxford Asymmetry International plc (“OAI”) in 2000 and today is one of the largest occupiers at Milton Park.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-opens-new-state-of-the-art-biology-facility-on-dorothy-crowfoot-hodgkin-campus-6328

Evotec SE, LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, today announced an agreement to boost early-stage innovations through access to Evotec’s leading shared end-to-end R&D platform.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-launch-of-partnering-agreement-to-strengthen-biotech-innovators-in-shared-rd-economy-6326

Evotec SE and Novo Nordisk today announced LAB eN², a translational drug discovery accelerator that aims to nurture early research from academic institutions into novel therapeutics. The focus is on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders. LAB eN² is a unique engagement model that combines Evotec’s multimodality drug discovery and pre-clinical development capabilities with Novo Nordisk’s therapeutic, clinical, and commercial expertise. LAB eN² has already signed on four academic institutions to participate: Harvard University, Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-novo-nordisk-launch-lab-en2-to-accelerate-translation-in-cardiometabolic-diseases-6324

Evotec SE today announced its financial results and corporate updates for the first half-year of 2023. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-results-for-the-first-half-year-2023-and-provides-corporate-updates-6322

Evotec SE will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-first-half-year-2023-results-on-29-august-2023-6320